Dicerna is a private, venture-backed biopharmaceutical company harnessing RNA interference (RNAi) to develop breakthrough, targeted therapeutics. Utilizing its Dicer Substrate Technology platform and EnCore delivery technology, Dicerna is developing a pipeline of programs to reach previously undruggable intracellular disease targets. The company has collaborations and alliances with global pharmaceutical companies and will continue to build on this momentum to advance its research and development efforts.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/01/13 | $60,000,000 | Series C |
Abingworth Brookside Capital Deerfield Management Company, L.P. Domain Associates Omega Funds RA Capital SR One | undisclosed |
